Effectiveness and impact of rotavirus vaccines in the United States-2006-2012

Expert Review of Vaccines

Volumn 13, Issue 3, 2014, Pages 365-376

  Rha, Brian ^a,b   Tate, Jacqueline E ^a   Payne, Daniel C ^a   Cortese, Margaret M ^a   Lopman, Benjamin A ^a   Curns, Aaron T ^a   Parashar, Umesh D ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Vaccines

Indexed keywords

CHILD; CHILD, PRESCHOOL; GASTROENTERITIS; HUMANS; INFANT; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; UNITED STATES; VACCINATION; VACCINES, ATTENUATED;

EID: 84894055481     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.877846     Document Type: Review

References (57)

1. Jin S, Kilgore PE, Holman RC, et al. Trends in hospitalizations for diarrhea in United States children from 1979 through 1992: estimates of the morbidity associated with rotavirus. Pediatr Infect Dis J 1996; 15(5):397-404
2. Charles MD, Holman RC, Curns AT, et al. Hospitalizations associated with rotavirus gastroenteritis in the United States, 1993-2002. Pediatr Infect Dis J 2006;25(6): 489-93
3. Malek MA, Curns AT, Holman RC, et al. Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics 2006;117(6):1887-92
4. Fischer TK, Viboud C, Parashar U, et al. Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States, 1993-2003. J Infect Dis 2007;195(8):1117-25
5. Payne DC, Staat MA, Edwards KM, et al. Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States. Pediatrics 2008;122(6): 1235-43
6. Widdowson MA, Meltzer MI, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007;119(4):684-97
7. Esposito DH, Holman RC, Haberling DL, et al. Baseline estimates of diarrheaassociated mortality among United States children before rotavirus vaccine introduction. Pediatr Infect Dis J 2011; 30(11):942-7
8. Kilgore PE, Holman RC, Clarke MJ, Glass RI. Trends of diarrheal disease- associated mortality in US children. 1968; JAMA 1995;274(14):1143-8
9. Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis 1996; 174(Suppl 1):S5-11
10. Cortese MM, Parashar UD; CDC. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009; 58(RR-2):1-25
11. Parashar UD, Alexander JP, Glass RI; Advisory Committee on Immunization Practices; CDC. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-12):1-13
12. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354(1):23-33
13. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354(1):11-22
14. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007;370(9601):1757-63
15. Tate JE, Cortese MM, Payne DC, et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J 2011; 30(1 Suppl):S56.60 . Detailed summary of the US post-licensure data of vaccine uptake, effectiveness and impact in the first 3 years after vaccine introduction.
16. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010;125(2):e199-207
17. Boom JA, Tate JE, Sahni LC, et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr Infect Dis J 2010; 29(12):1133-5
18. Guh AY, Hadler JL. Use of the state immunization information system to assess rotavirus vaccine effectiveness in Connecticut, 2006-2008. Vaccine 2011; 29(37):6155-8
19. Wang FT, Mast TC, Glass RJ, et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010;125(2): e208-13
20. Wang FT, Mast TC, Glass RJ, et al. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States. Pediatr Infect Dis J 2013;32(3):278-83
21. Cortes JE, Curns AT, Tate JE, et al. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N Engl J Med 2011;365(12):1108-17 . Analyses of large US insurance claims database estimated reduction of approximately 65,000 diarrheal hospitalizations and US$ 278 million in cost savings in two post-vaccine seasons during 2007-2009.
22. Staat MA, Payne DC, Donauer S, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics 2011; 128(2):e267-75
23. Payne DC, Boom JA, Staat MA, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis 2013;57(1):1320 . RV5 and RV1 vaccine effectiveness assessed in multi-center active, population-based surveillance system. No evidence of waning immunity observed through fourth year of life for RV5, and second year of life for RV1. Protection against heterotypic strains observed.
24. Cortese MM, Leblanc J, White KE, et al. Leveraging state immunization information systems to measure the effectiveness of rotavirus vaccine. Pediatrics 2011;128(6): e1474-81
25. Cortese MM, Immergluck LC, Held M, et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics 2013;132(1):e25-33
26. Desai SN, Esposito DB, Shapiro ED, et al. Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA. Vaccine 2010;28(47): 7501-6
27. CDC. Delayed onset and diminished magnitude of rotavirus activity - United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008; 57(25):697-700
28. Tate JE, Panozzo CA, Payne DC, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009;124(2): 465-71
29. CDC. Reduction in rotavirus after vaccine introduction-United States, 2000-2009. MMWR Morb Mortal Wkly Rep 2009; 58(41):1146-9
30. Tate JE, Mutuc JD, Panozzo CA, et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J 2011;30(1 Suppl):S30-4 . Most recent summary of national trends of rotavirus activity before and after vaccine introduction based on passive laboratory-based surveillance.
31. Tate JE, Haynes A, Payne DC, et al. Trends in national rotavirus activity before and after introduction of rotavirus vaccine into the national immunization program in the United States, 2000 to 2012. Pediatr Infect Dis J 2013;32(7):741-4
32. Pitzer VE, Atkins KE, de Blasio BF, et al. Direct and indirect effects of rotavirus vaccination: comparing predictions from transmission dynamic models. PLoS ONE 2012;7(8):e42320
33. Curns AT, Panozzo CA, Tate JE, et al. Remarkable postvaccination spatiotemporal changes in United States rotavirus activity. Pediatr Infect Dis J 2011;30(1 Suppl):S54-5
34. Curns AT, Steiner CA, Barrett M, et al. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010;201(11):1617-24
35. Cortese MM, Tate JE, Simonsen L, et al. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatr Infect Dis J 2010;29(6): 489-94
36. Begue RE, Perrin K. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice. Pediatrics 2010;126(1):e40-5
37. Yen C, Tate JE, Wenk JD, et al. Diarrhea-associated hospitalizations among US children over 2 rotavirus seasons after vaccine introduction. Pediatrics 2011; 127(1):e9-e15
38. Payne DC, Staat MA, Edwards KM, et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis 2011;53(3):245-53
39. Desai R, Curns AT, Steiner CA, et al. All-cause gastroenteritis and rotavirus-coded hospitalizations among US children, 2000-2009. Clin Infect Dis 2012;55(4): e28-34
40. Anderson EJ, Rupp A, Shulman ST, et al. Impact of rotavirus vaccination on hospital-acquired rotavirus gastroenteritis in children. Pediatrics 2011;127(2):e264-70
41. Guerra AH, Stockmann C, Pavia AT, et al. Laboratory-confirmed rotavirus disease in Utah children: clinical and economic impact of rotavirus vaccination. J Pediatr Infect Dis Soc 2012;1(4):268-77
42. Williams DJ, Edwards KM, Payne DC, et al. Decline in gastroenteritis- related triage calls after rotavirus vaccine licensure. Pediatrics 2012;130(4):e872-8
43. Desai R, Haberling D, Holman RC, et al. Impact of rotavirus vaccine on diarrhea-associated disease burden among American Indian and Alaska Native children. Pediatrics 2012;129(4):e907-13
44. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011;204(7):980-6 . Demonstrated indirect benefits of rotavirus vaccination extended to unvaccinated 5- to 24-year-old age group, which accounted for approximately 15% of averted hospitalizations in 2008.
45. Gastanaduy PA, Curns AT, Parashar UD, Lopman BA. Gastroenteritis hospitalizations in older children and adults in the United States before and after implementation of infant rotavirus vaccination. JAMA 2013; 310(8):851-3
46. Anderson EJ, Shippee DB, Weinrobe MH, et al. Indirect protection of adults from rotavirus by pediatric rotavirus vaccination. Clin Infect Dis 2013;56(6):755-60
47. Patel MM, Steele D, Gentsch JR, et al. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011;30(1 Suppl):S1-5
48. Vesikari T, Uhari M, Renko M, et al. Impact and Effectiveness of Rotateq(R) Vaccine based on three years of surveillance following introduction of a rotavirus immunization program in Finland. Pediatr Infect Dis J 2013. [Epub ahead of print]
49. Field EJ, Vally H, Grimwood K, Lambert SB. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010;126(3):e506-12
50. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 2010;201(3): 363-9
51. Yen C, Figueroa JR, Uribe ES, et al. Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in Mexico. J Infect Dis 2011;204(5):783-6
52. Steele AD, Neuzil KM, Cunliffe NA, et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infect Dis 2012;12:213
53. Patel MM, Patzi M, Pastor D, et al. Effectiveness of monovalent rotavirus vaccine in Bolivia: case-control study. BMJ 2013;346:f3726
54. Patel MM, Lopez-Collada VR, Bulhoes MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011; 364(24):2283-92
55. Carlin JB, Macartney KK, Lee KJ, et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program. Clin Infect Dis 2013;57(10):1427-34
56. Haber P, Patel M, Pan Y, et al. Intussusception after rotavirus vaccines reported to US VAERS, 2006-2012. Pediatrics 2013;131(6):1042-9
57. ACIP Advisory Committee on Immunization Practices Meeting Summary Report; 19 - 20 June 2013, Atlanta, GA, USA